Department of Health and Human Services, through National Institutes of Health, awarded Cnd Life Sciences, Inc. of Scottsdale, AZ $2,289,462 under the SBIR program (Phase II), with work starting 2025-09-05 and running to 2028-08-31. It is the only SBIR or STTR award to Cnd Life Sciences, Inc. in the last two years. Each figure links to the federal record.
The award
| Recipient | Cnd Life Sciences, Inc. (Scottsdale, AZ) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase II |
| Amount obligated | $2,289,462 |
| Period of performance starts | 2025-09-05 |
| Period of performance ends | 2028-08-31 |
| Award number | R44NS143486 (grant, CFDA 93.853) |
| Assistance listing | 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders |
| Place of performance | Scottsdale, Maricopa County, AZ |
| Signed | 2025-08-27 |
| Recipient registry id (UEI) | N8BNGXXEBP75 |
Want the whole picture on Cnd Life Sciences, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cnd Life Sciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cnd Life Sciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
Analysis of cutaneous phosphorylated alpha-synuclein to identify patients at risk of progressing from essential tremor to parkinson's disease - project summary—in this direct-to-Phase II SBIR, cnd life sciences proposes
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-09-07 | Continuation | 000 | $1,012,800 |
| 2025-09-25 | Revision | 001 | $0 |
| 2025-08-27 | New | 000 | $1,276,662 |
Analysis of cutaneous phosphorylated alpha-synuclein to identify patients at risk of progressing from essential tremor to parkinson's disease - project summary—in this direct-to-Phase II SBIR, cnd life sciences proposes to 1) advance the development of a test to identify patients with essential tremor (et) who have deposits of phosphorylated a- synuclein (p-syn), a pathological hallmark of parkinson’s disease (pd), and 2) determine whether the test can predict which patients will phenoconvert to pd. Et is the most common movement disorder, affecting more than 5% of people over 60 and ~ 20% of people over 80. Each year, ~ 1% of patients with et develop pd—a rate almost 10 times higher than in older adults without et. Because the treatments and clinical course of et and pd differ substantially, there is a pressing need to identify patients who are at risk for phenoconversion from et to pd. In pd, progressive deposition of p-syn in the central and peripheral nervous systems is associated with a progressive degeneration of nerve fibers and loss of motor functions. Recent post-mortem analyses showed that p-syn is present in the brains of about 25% of patients with et, and ~ 80% of these p-syn-positive individuals exhibited “soft” neurological features of pd prior to death. Unfortunately, the current confirmatory test for pd (i.e., dat scan) is insensitive early in the disease course ...
From the federal award record.
Every other federal award to Cnd Life Sciences, Inc. on record
The federal register lists 5 other awards to the same registry id (UEI N8BNGXXEBP75), $7,966,389 in all, from 3 agencies.
| Starts | Agency | Amount | Award |
|---|---|---|---|
| 2025-08-15 | Department of Veterans Affairs | $140,168 | Synone esoteric testing services (36C25025P1427) |
| 2023-09-25 | Department of the Army | $5,636 | UC187 FY22 - syn-one testing (W81K0023P0251) |
| 2022-09-15 | National Institutes of Health | $3,000,000 | Cutaneous phosphorylated alpha-synuclein for detection of prodromal synucleinopathies - project summary a grou (R44NS127696) |
| 2022-04-01 | National Institutes of Health | $2,408,271 | A diagnostic test for dementia with lewy bodies - summary the objective of this study is to validate a diagnos (R44AG076072) |
| 2020-09-30 | National Institutes of Health | $2,412,314 | Phs 2019-02 omnibus solicitation of the NIH, CDC, and FDA for small business innovation research grant applica (R44NS117214) |
More on Cnd Life Sciences, Inc.
Cnd Life Sciences, Inc.'s funding history and team
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Cnd Life Sciences, Inc.Look up Cnd Life Sciences, Inc. first. Finding the company and seeing how much is on record uses no credits.
Look up Cnd Life Sciences, Inc.Where this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.